Accession Therapeutics Limited
David Cole has a diverse work experience in the field of research and molecular science. David is currently working as the Head of Research and Head of Molecular Science at Accession Therapeutics Limited since August 2021. Prior to this, they held the role of Associate Director of Disease Biology Oncology and Collaboration and Discovery Research Lead at Immunocore from December 2016 to August 2021. David also has experience working at Cardiff University where they served as a Wellcome Trust Fellow, Leverhulm Research Fellow, and Postdoctoral Research Associate. In addition, they are an Honorary Professor at Cardiff University since April 2023. David Cole's work primarily focuses on understanding T-cell recognition during infectious disease, cancer, and autoimmunity.
David Cole completed their Bachelor of Science (BS) degree in Biology, General at Brunel University London from 1999 to 2003. Following this, they pursued a Doctor of Philosophy (PhD) degree in Molecular Immunology at the University of Oxford, completing it from 2003 to 2006.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.